29 - 31 October, 2019 | Twickenham Stadium, London, United Kingdom
Zoe Coughlin, Associate Director CMC at Immatics

Zoe Coughlin

Associate Director CMC

Check out the incredible speaker line-up to see who will be joining Zoe.

Download The Latest Agenda

Conference Day 2

Wednesday, September 13th, 2017

9:45 AM Manufacturing Of TCR-Based T-Cell Therapies For Solid Cancers To Enable Late Stage Clinical Trials

- Hear how Immatics proprietary discovery platforms, XPRESIDENT® and XCEPTOR®, identifies the targets and TCRs that are used as the basis of the various Immatics adoptive cell therapy programs
- Examine the development of autologous and allogeneic T-cell products for solid cancers using Immatics targets and TCRs
- Discuss the products that have been developed and manufactured under cGMP conditions to meet the pre-set release criteria for patient infusion of the Immatics 4 active Phase I clinical trials
- Develop the next generation of manufacturing processes for implementation in late stage clinical trials and commercialisation